Cullen G. Taylor

Cullen G. Taylor

Northern Virginia

Email cullen.taylor@​

Phone +1 703 610 6177

Fax +1 703 610 6200

LanguagesEnglish, Spanish

Practice groupIntellectual Property, Media, and Technology

Cullen Taylor helps companies structure and negotiate their most complex commercial transactions, particularly those involving the development, acquisition, and commercialization of intellectual property and technology. Cullen takes a practical, results-oriented approach to getting deals done, drawing on his broad experience across multiple industries to anticipate and address problems before they arise.

Trained as an intellectual property lawyer, Cullen understands the technical and business issues that arise as parties enter, live under, and exit long-term commercial arrangements. Cullen is skilled at structuring and drafting contracts that address these concerns while keeping the client's business goals at front and center.

Cullen focuses his practice primarily on the life sciences industry, where he handles a variety of transactions, including product acquisition, licensing, research and development, collaboration, co-promotion, supply, and distribution agreements. His clients include pharmaceutical and biotechnology companies and device and diagnostics manufacturers with products and therapies at all stages of development. Cullen is often called upon to advise such clients on discovering, developing, and acquiring cutting-edge therapies and innovative technologies.

Cullen is Co-Head (Americas) of the firm's Life Sciences Transactions team. He regularly collaborates with his colleagues in the firm's Corporate practice to address intellectual property and technology-related issues that arise in mergers, acquisitions, and other corporate transactions.

Cullen was recently recognized by Managing IP as the 2021 IP Transactional Lawyer of the Year for the Americas.

Awards and recognitions


Practitioner of the Year (IP Transactions)
Managing IP


BTI Client Service All-Star
BTI Consulting Group

2008, 2010, 2015, 2019

Rising Star
Virginia Super Lawyers


Rising Star
Washington, D.C. Super Lawyers


Intellectual Property
Virginia Legal Elite


Young Lawyer
Virginia Legal Elite


Health Law
Virginia Legal Elite


Media, Technology, and Telecoms: Technology Transactions
Legal 500 US

Education and admissions


J.D., Harvard Law School, 2000

B.A., University of Virginia, with distinction, Phi Beta Kappa, 1997


Member, American Bar Association

Member, Licensing Executives Society

Member, Raven Society

Member, Virginia Bar Association

Bar admissions and qualifications


Representative experience

Representing Gilead Sciences in its collaboration with Merck & Co. to co-develop and co-commercialize long-acting HIV combination therapies.

Representing Daiichi Sankyo in its collaboration with AstraZeneca to develop and commercialize Daiichi Sankyo's DS-1062, a potential treatment for multiple tumor types.

Representing Gilead Sciences and Kite Pharma in a collaboration and license arrangement with oNKo-Innate to develop next-generation drug and engineered cell therapies focused on natural killer cells.

Representing Gilead Sciences in its collaboration with Yuhan Corporation to co-develop novel therapeutics for patients with advanced fibrosis due to NASH.

Representing Incyte Corporation in its license and collaboration agreement with MacroGenics relating to an anti-PD-1 antibody.

Representing multiple pharmaceutical companies and diagnostics manufacturers in collaboration agreements to develop companion diagnostics for drug products.

Representing Regeneron in a genomics collaboration with Geisinger Health Systems.

Representing Helsinn Healthcare in connection with license and collaboration agreements with MEI Pharma and Taiho Pharmaceuticals.

Representing Cormedix in various license, collaboration, supply, and distribution agreements relating to its Neutrolin product.

Representing Daiichi Sankyo in its co-commercialization agreement with AstraZeneca relating to MOVANTIK in the United States.

Representing Naver on the acquisition of Xerox Research Centre Europe.

Representing Novartis in the sale of its animal health business to Eli Lilly for approximately US$5.4bn.

Loading data